LambdaVision develops an injectable, protein‑based artificial retina that replaces lost photoreceptor function by delivering rhodopsin‑mimetic proteins produced in low‑gravity microfluidic bioreactors. The GMP‑compliant, space‑manufactured proteins are formulated in a biodegradable hydrogel and administered via a 23‑gauge sub‑retinal delivery system with OCT guidance, targeting ophthalmic surgeons and retinal specialty clinics treating advanced RP and AMD.
Funding
Funding not disclosed
SSFounders
Product
Problem
Patients with advanced retinal degenerative diseases such as retinitis pigmentosa (RP) and age‑related macular degeneration (AMD) lose functional photoreceptor cells, leaving them blind or with severely limited vision. Existing treatments cannot replace the lost light‑sensing capability, creating a therapeutic gap for late‑stage disease. The scarcity of high‑purity, biologically active retinal proteins further hampers development of cell‑free vision restoration approaches.
Solution
LambdaVision engineers a protein‑based artificial retina that substitutes the light‑absorbing function of native photoreceptors. By expressing rhodopsin‑analog proteins in a microgravity environment, the company achieves superior folding, post‑translational modification, and crystallinity compared with Earth‑based production. The purified proteins are formulated into an injectable depot that integrates into the outer retina, where they transduce photons into neural signals compatible with existing retinal circuitry. An on‑board delivery device enables minimally invasive sub‑retinal injection, reducing surgical complexity. Preclinical studies demonstrate restored visual acuity and electrophysiological responses in animal models of RP and AMD. The platform leverages a scalable low‑Earth‑orbit manufacturing pipeline that aligns with GMP standards, facilitating rapid transition to human trials. Regulatory strategy targets an IND submission followed by a Phase I/II safety‑efficacy pathway for patients with end‑stage retinal degeneration.
Target Audience
Primary customers are ophthalmic surgeons and retinal specialty clinics treating advanced RP and AMD, as well as pharmaceutical partners seeking a biologics platform for vision restoration. Payers and health‑system formulary committees are also targeted for reimbursement planning once clinical efficacy is established.
Features
- Recombinant rhodopsin‑mimetic proteins produced in low‑gravity microfluidic bioreactors, yielding >95 % correctly folded active conformers
- End‑to‑end GMP‑compliant space‑based manufacturing workflow with in‑orbit purification and cryogenic stabilization
- Injectable, biodegradable hydrogel matrix that self‑assembles in the sub‑retinal space and anchors proteins to the photoreceptor layer
- Minimally invasive 23‑gauge sub‑retinal delivery system with real‑time optical coherence tomography (OCT) guidance
- Preclinical efficacy demonstrated in rodent and large‑animal models, showing ≥2 log improvement in visual‑evoked potentials
- Integrated analytics platform for batch release testing, including mass spectrometry, circular dichroism, and functional phototransduction assays
- Scalable production capacity targeting >10 k doses per year within three years of launch
- Regulatory‑ready documentation package supporting IND filing under the FDA’s biologics pathway